Nutrition Sciences Graduate Program, Department of Nutrition, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, RS, Brasil.
Gastronomy Undergraduate Course, Department of Nutrition, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, RS, Brasil.
Nutr Rev. 2024 Dec 1;82(12):1710-1725. doi: 10.1093/nutrit/nuad164.
Olive leaf extract (OLE) is rich in phenolic compounds, which are known for their health benefits. Cardiovascular diseases, primarily coronary heart disease and stroke, are leading causes of mortality globally.
This systematic review aimed to assess the impact of OLE on cardiometabolic risk factors in adults. The selection of studies was based on intervention and outcomes, using relevant search descriptors.
The databases PubMed, EMBASE, and Web of Science were systematically searched for pertinent studies published up to August 2021.
Only randomized clinical trials, either cross-over or parallel, involving adult individuals aged ≥18 years, were considered. Additionally, trials that had a comparative or placebo group and used pure OLEs for oral treatment were included.
Twelve randomized clinical trials (RCTs) met the inclusion criteria. These trials had follow-up periods ranging from 2 days to 12 weeks and involved 703 patients aged 18 years-79 years. The outcomes demonstrated a positive correlation between the intervention group and glucose metabolism (4 RCTs), blood pressure (2 RCTs), lipid profile (2 RCTs), and inflammatory markers (2 RCTs). The RoB2 tool and the GRADE system were used to evaluate the risk of bias and the quality of evidence in the studies.
In the meta-analysis, fasting glycemia, as evaluated in studies using a low dose of OLE, showed a significant result favoring the control group. To obtain more consistent results, further clinical studies in humans, using similar methodologies, are required.
PROSPERO registration no. CRD42020200877.
橄榄叶提取物（OLE）富含酚类化合物，具有多种健康益处。心血管疾病，主要是冠心病和中风，是全球范围内主要的死亡原因。
本系统评价旨在评估 OLE 对成年人心脏代谢危险因素的影响。研究的选择基于干预和结果，使用了相关的搜索描述符。
系统地检索了 PubMed、EMBASE 和 Web of Science 数据库，以获取截至 2021 年 8 月发表的相关研究。
仅纳入了随机临床试验，无论是交叉还是平行设计，涉及年龄≥18 岁的成年个体。此外，还纳入了比较组或安慰剂组，以及使用口服纯 OLE 治疗的试验。
符合纳入标准的共有 12 项随机临床试验（RCT）。这些试验的随访时间从 2 天到 12 周不等，共涉及 703 名年龄在 18 岁至 79 岁之间的患者。结果表明，干预组与葡萄糖代谢（4 项 RCT）、血压（2 项 RCT）、血脂谱（2 项 RCT）和炎症标志物（2 项 RCT）之间存在正相关。使用 RoB2 工具和 GRADE 系统评估了研究中的偏倚风险和证据质量。
在荟萃分析中，使用低剂量 OLE 进行评估的空腹血糖显示出有利于对照组的显著结果。为了获得更一致的结果，需要在人类中使用类似方法进行进一步的临床研究。
PROSPERO 注册号 CRD42020200877。
Zotero 插件